What the hell you are talking about. The price of the company is over $1.5 billion. You cannot find any small medical company with so many promising pipe line and 2 important approved drugs.
CEO change was a good strategy that benefit the company, CEO and all shareholders.
It is a possibility not to be ruled out yet. However, with partnerships already established an outright sale would be a bit more complicated wouldn't it?
I am predicting a more steady rise to $14 or higher towards end of the year as folks realize the potential. There are a few driving forces that are important.
1) As martin pointed out the CEO comp increase linked to $16 stock price
2) with Yueno still holding 20Million of scmp stock he would definitely want to retire with this valued over $16.
3) Yeno is focussed on earning dividends for the huge volume of scmp he holds.
4) ofcourse the pipeline (spinal stenosis, amitiza in europe etc).